Alta Partners

Alta Partners is a venture capital fund manager devoted exclusively to the life sciences. Historically, the firm invested out of two separate fund families. The Alta California Partners (ACP) funds were dedicated to early-stage investments, while the Alta BioPharma (ABP) series focused on later-stage private companies and early public companies. ACP IV marked Alta's shift towards a singular focus on life sciences investing, and in 2006, the firm launched Alta Partners VIII, its first stage-agnostic fund.

Robert Alexander

Director

Peter Hudson

MD

Daniel S. Janney

MD

Bob More

MD

Larry Randall

CFO

Adam L. Tomasi

Principal

260 past transactions

ImmuneID

Series A in 2021
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.

Nereus Pharmaceuticals

Series E in 2010
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

Phenomix

Series A in 2004
As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

Xelerated

Series E in 2008
Xelerated Inc. operates as a fabless semiconductor company. The company provides HX devices that offer wirespeed performance and cover a range of applications from carrier backbone platforms to access aggregation and enterprise switching systems; and Xelerator devices, which are network processors. It also offers a Software Development Kit that delivers an integrated development environment for developing, simulating, debugging, and testing forwarding plane applications for Xelerator network processors, as well as supports Xelerated's HX carrier Ethernet network processors and AX programmable Ethernet switches. In addition, the company provides Reference Design Kits, which are network processor development platforms for Xelerator network processors; and Precision Time Solution, which provides hardware and software support for Precision Time Protocol and Synchronous Ethernet. Further, it offers solutions for data aware transport platforms, switches/routers, metro Ethernet switches, and access equipment. The company was formerly known as Xelerated Packet Devices and changed its name to Xelerated Inc. in January 2002. The company was founded in 2000 and is headquartered in Santa Clara, California with additional offices in Tel Aviv, Israel; Beijing, China; and Stockholm, Sweden.

Taligen Therapeutics

Series B in 2010
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process.

Arete Therapeutics

Series A in 2007
Arete Therapeutics Inc. is discovering and developing first-in-class small molecule compounds.

Wavtrace

Venture Round in 1999
Wavtrace is focused on the development of broadband wireless access systems that focus on the transmission of voice and video data. Wavtrace was founded by Robert Lundy and Vern Fotheringham in 1996. It is based in Bellevue, Washington.

Renovis

Series B in 2002
Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.

7TM Pharma

Series D in 2007
7TM Pharma is a biotech company that discovers and develops drugs with a primary therapeutic focus on diabetes, gastrointestinal, metabolic, asthma, and vascular diseases. The company offers seven transmembrane-spanning receptors, including TM38837, a small molecule CB1 receptor antagonist; TM30339, a NPY Y4 selective agonist that is used within gastrointestinal disorders, and short bowel syndrome; and CRTH2 antagonist, an oral drug for inflammatory or respiratory diseases. 7TM Pharma was founded in 2000 and is based in Lyngby, Hovedstaden.

AGY Therapeutics

Series C in 2004
AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform for functional gene discovery and mapping out specific pathways underlying central nervous system diseases. By harnessing these capabilities, AGY identified potential target proteins that can be modulated to block the progression of the disease process. This is paving the way for novel CNS therapeutics and future growth for AGY.

CymaBay Therapeutics

Series B in 2004
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

DispatchHealth

Private Placement in 2020
DispatchHealth Management, LLC provides on-demand mobile and virtual healthcare services. It offers services in the areas of acute injury and illness evaluation, laceration suture repair, injured extremity splinting, epistaxis treatment (nosebleeds), Foley catheter placement, G-tube placement, medication administration, laboratory testing, outpatient imaging arrangement (X-ray and CT scan), and primary care physician and home health agency coordination aspects. It serves patients and families. The company was formerly known as True North Health Navigation, LLC. DispatchHealth Management, LLC was founded in 2013 and is based in Denver, Colorado.

Immune Design

Series A in 2008
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

Phenomix

Series B in 2005
As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

DispatchHealth

Series B in 2019
DispatchHealth Management, LLC provides on-demand mobile and virtual healthcare services. It offers services in the areas of acute injury and illness evaluation, laceration suture repair, injured extremity splinting, epistaxis treatment (nosebleeds), Foley catheter placement, G-tube placement, medication administration, laboratory testing, outpatient imaging arrangement (X-ray and CT scan), and primary care physician and home health agency coordination aspects. It serves patients and families. The company was formerly known as True North Health Navigation, LLC. DispatchHealth Management, LLC was founded in 2013 and is based in Denver, Colorado.

TorreyPines Therapeutics

Series C in 2005
TorreyPines Therapeutics engages in the discovery and development of small molecule compounds in the United States. Its product portfolio includes both candidates from its drug targeting platforms and in-licensed and acquired product candidates. As of August 31, 2010, its pipeline includes three clinical development programs. It also has three other clinical-stage product candidates, for which it is seeking business development partners, and it has four preclinical product candidates it is developing, three of which are based upon its drug-targeting platforms.

Zafgen

Series E in 2013
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Aegis Semiconductor

Series C in 2004
Aegis is a privately held company that builds solutions for embedded monitoring of advanced optical networks. The company's Active Thin Films are manufactured using proven high-volume processes with demonstrated high yield and superb uniformity. Aegis's solutions benefit from the reliability of solid-state, silicon-based design, extreme scalability, and low-cost packaging architectures.

Aegerion Pharmaceuticals

Series A in 2006
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.

Evofem Biosciences

Series C in 2014
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Chimerix

Series D in 2007
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

AGTC

Series B in 2012
Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.

Sutro Biopharma

Series C in 2010
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Agensys

Series D in 2007
Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.

Terawave Communications

Series B in 2000
Terawave Communications, Inc. manufactures converged access and multi-service networking solutions. Its multi-service aggregation and passive optical network products provide data, voice, video, and circuit service convergence solutions. The company serves service providers, government agencies, and enterprise customers in the United States, Europe, Asia, Africa, and Latin America. Terawave Communications has locations in North America, Europe, and Asia. The company was founded in 1998 and is based in Hayward, California with additional offices in the United States of America, Canada, Asia, and Europe. As of October 25, 2007, Terawave Communications, Inc. is a subsidiary of Occam Networks Inc. (NasdaqNM:OCNW).

Hangzhou Qihan Biotechnology Co., Ltd.

Private Placement in 2018
Hangzhou Qihan Biotechnology Co., Ltd. provides genetic editing and xenotransplantation research and development for tissues and organs that can be transplanted to patients. The company was founded in 2017 and is based in Hangzhou, China.

Sierra Surgical

Series B in 2008
Sierra Surgical Technologies develops minimally invasive surgical systems. The company develops female sterilization technology. Sierra Surgical Technologies, Inc. is based in Palo Alto, California.

NeurogesX

Series C in 2004
NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel non-opioid, pain management therapies to address unmet medical needs. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is based in San Mateo, California.

Nanomix

Series D in 2007
Nanomix, Inc. develops automated point-of-care diagnostic systems. Its products include Nanōmix eLab® System, an automated system that consists of a handheld reader and an integrated assay cartridge with a proprietary biosensor; Sepsis Panel a tool for the physician to use in diagnosing sepsis within the 30 minute critical clinical window for decisions about care; and Nanōmix eLab platform for laboratory diagnostics at the point of care. Nanomix, Inc. was formerly known as Covalent Materials, Inc. and changed its name to Nanomix, Inc. in April 2002. The company was founded in 2000 and is based in Emeryville, California.

RedShift BioAnalytics

Series A in 2006
RedShiftBio provides an infrared technology with advanced data analytics to facilitate better, faster decision making in biopharmaceutical development from discovery to market via the direct measurement of previously undetectable change in protein structural attributes critical to drug product efficacy and quality. It has developed a Microfluidic Modulation Spectroscopy (MMS) platform in response to a customer’s request for a better solution, and rather than repurpose outdated tools and methods designed originally for other applications. They started a new and developed MMS from the ground up specifically with the protein scientist in mind. The company was founded in 2005 and is headquartered in Burlington, Massachusetts.
Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening. Our initial research has been with mifepristone, which potently blocks the cortisol receptor. On February 17, 2012, the FDA approved Korlym® (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.

Nanomix

Series C in 2005
Nanomix, Inc. develops automated point-of-care diagnostic systems. Its products include Nanōmix eLab® System, an automated system that consists of a handheld reader and an integrated assay cartridge with a proprietary biosensor; Sepsis Panel a tool for the physician to use in diagnosing sepsis within the 30 minute critical clinical window for decisions about care; and Nanōmix eLab platform for laboratory diagnostics at the point of care. Nanomix, Inc. was formerly known as Covalent Materials, Inc. and changed its name to Nanomix, Inc. in April 2002. The company was founded in 2000 and is based in Emeryville, California.

Netli

Venture Round in 2004
Netli provides a number of corporate network and Internet services, including hosting, storage, and security services. Customers include Hewlett-Packard , Motorola, and Millipore. Netli has received equity financing from Reed Elsevier Ventures, Morgenthaler Ventures, Bessemer Venture Partners, and Alta Partners, among others. The company has offices in the US and Hong Kong. Netli was acquired by content and application acceleration specialist Akamai Technologies in 2007.
Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.

SARcode Bioscience

Venture Round in 2006
SARcode Corporation is a private San Francisco based biopharmaceutical company engaged in the development of a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; αLβ2) antagonists as a topical agent for the treatment of significant unmet medical needs in ophthalmology, dermatology and other inflammatory diseases.

Novome Biotechnologies

Private Placement in 2020
Novome Biotechnologies, Inc. engineers and develops bacteria from the human gut to treat diseases. Its platform enables controllable engraftment of genetically engineered microbial medicines in the gut for sustained therapies. The company’s synthetic biology tools allow to plug into ecosystem and deliver precise activities to treat chronic diseases. Novome Biotechnologies, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Lumena Pharmaceuticals

Series A in 2013
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults.

Nanomix

Series A in 2001
Nanomix, Inc. develops automated point-of-care diagnostic systems. Its products include Nanōmix eLab® System, an automated system that consists of a handheld reader and an integrated assay cartridge with a proprietary biosensor; Sepsis Panel a tool for the physician to use in diagnosing sepsis within the 30 minute critical clinical window for decisions about care; and Nanōmix eLab platform for laboratory diagnostics at the point of care. Nanomix, Inc. was formerly known as Covalent Materials, Inc. and changed its name to Nanomix, Inc. in April 2002. The company was founded in 2000 and is based in Emeryville, California.

The Medicines Company

Venture Round in 1999
The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.

Coapt Systems

Series E in 2007
Coapt Systems, Inc. engages in the design, development, manufacture, and marketing of bio-absorbable implants for use in soft tissue fixation during facial cosmetic surgery procedures. It offers ENDOTINE Forehead 3.0, a bioabsorbable brow fixation device; ENDOTINE Forehead Instrument Kits that comprise insertion tools, drill bits, and sterilization trays with lids; ENDOTINE Triple 3.0, the bioabsorbable brow fixation devices with disposable drill bits and insertion tools; ENDOTINE TransBleph 3.0, a bioabsorbable upper lid and brow fixation devices. The company also provides ENDOTINE Midface ST 4.5, a bioabsorbable midface suspension devices; ENDOTINE Ribbon, a bioabsorbable fixation devices; Coapt Manual Surgical Drills, the manual surgical hand drills for use with ENDOTINE implants; and SurgiWire Incisionless Dissectors, the subcutaneous The Endotine product line was bought by MicroAire, a surgical device manufacturer in Charlottesville, VA, in August 2010.

Intradigm Corporation

Series B in 2009
Private biotechnology company that develops systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's expertise in drug development and delivery serves as the foundation of Intradigm RNAi platform. In particular, the company proprietary RNAi Nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through systemic administration of the drug product.

Sanarus Medical

Series D in 2005
Sanarus Medical, Inc. develops and markets minimally invasive devices for the diagnosis and treatment of breast tumors. It offers Visica treatment system for cryoablation of breast fibroadenomas; Cassi II rotational core biopsy system, an automated hand held breast biopsy device to secure contiguous biopsy samples; and ImarC tissue marker system, a line of breast tissue markers that are visible under imaging modalities. The company was founded in 1999 and is headquartered in Pleasanton, California.

Ablynx

Series C in 2006
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

eGenesis

Series A in 2017
Egenesis Inc., a biotechnology company, operates as a gene editing and genome engineering that develops human transplantable organs, tissues, and cells. It offers a gene editing platform for developing human compatible organs. The company also provides development, such as gene engineering, single cell cloning, somatic cell nuclear/embryo transfer, organ procurement, and transplantation. The company was incorporated in 2015 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

AGY Therapeutics

Series B in 2001
AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform for functional gene discovery and mapping out specific pathways underlying central nervous system diseases. By harnessing these capabilities, AGY identified potential target proteins that can be modulated to block the progression of the disease process. This is paving the way for novel CNS therapeutics and future growth for AGY.

Sutro Biopharma

Series B in 2007
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Nereus Pharmaceuticals

Series A in 2000
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

TransMedics

Series E in 2010
TransMedics, Inc. operates as a medical technology company. It offers organ care system, a multi-organ preservation technology that mirrors human physiology, minimizes ischemia, and provides the ability to optimize the organ during transport. The company is headquartered in Andover, Massachusetts.

Sutro Biopharma

Series B in 2009
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Abionyx Pharma

Series C in 2010
ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

Aegis Semiconductor

Series E in 2009
Aegis is a privately held company that builds solutions for embedded monitoring of advanced optical networks. The company's Active Thin Films are manufactured using proven high-volume processes with demonstrated high yield and superb uniformity. Aegis's solutions benefit from the reliability of solid-state, silicon-based design, extreme scalability, and low-cost packaging architectures.

PatientsLikeMe

Venture Round in 2021
PatientsLikeMe is a personalized health network of an integrated community, health management, and real-world data platform. It helps people find new options for treatments, connect with others, and take action to improve their outcomes. The company has worked with every major pharmaceutical company and a range of government organizations to bring the patient voice to research, development, and public policy. With more than 600,000 members, PatientsLikeMe is a trusted source for real-world disease information and a clinically robust resource that has published more than 100 research studies. The Boston, Massachusetts-located company was founded by Ben Heywood, James Heywood, and Jeff Cole in 2004

USGI Medical

Series B in 2003
USGI Medical, Inc. engages in the development of technologies that enable surgeons and gastroenterologists to perform procedures through the body's natural passageways. The company offers specialized tools to perform minimally invasive procedures through a patient's mouth or other natural orifices. It offers its products obesity, natural orifice translumenal endoscopic surgery, and gastroesophageal reflux disease. The company was incorporated in 2001 and is based in San Clemente, California.

SARcode Bioscience

Series A in 2007
SARcode Corporation is a private San Francisco based biopharmaceutical company engaged in the development of a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; αLβ2) antagonists as a topical agent for the treatment of significant unmet medical needs in ophthalmology, dermatology and other inflammatory diseases.

Tyra Biosciences

Private Placement in 2020
Tyra Biosciences, Inc. develops small molecule therapies for the treatment of cancer. It offers therapies to combat drug resistance in cancer treatments. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

nCircle Network Security

Series C in 2002
nCircle Network Security, Inc. provides agentless security risk and compliance management solutions. The company's products include IP360, the vulnerability and risk management solution that provides reporting, vulnerability prioritization, and remediation workflow designed to enable risk reduction; and Topology Risk Analyzer, which prioritizes vulnerabilities utilizing intelligence about the network layout. Its products also include Security Intelligence Hub, an open-architected reporting and integration point for collecting and sharing network intelligence across the enterprise security ecosystem; and nTellect, a threat prioritization system that leverages IP360's updated network intelligence to improve the accuracy and effectiveness of Cisco and McAfee's IDS and IPS. In addition, the company's products include Certified PCI Scan Service, an automated network security scan and reporting service, which enables customers to monitor and report on compliance with the PCI security standard; and Security Policy and Regulatory Compliance Solutions that compliance with internal security policies and automate security process, as well as support government- regulatory compliance solutions for FISMA and IAVA. It also provides configuration and regulatory compliance, reporting and analytics, and government solutions. The company offers vulnerabilities and exposures research team, consulting, and training services. Its security solutions are used by financial services, energy, utilities, retail, consumer goods, healthcare, pharmaceuticals, government, media, leisure, and technology enterprises, as well as government agencies and service providers to identify, measure, manage, and reduce security risk and automate compliance on their networks. The company was formerly known as Hiverworld, Inc. nCircle Network Security, Inc. was founded in 1998 and is headquartered in San Francisco, California with regional offices in Atlanta, Toronto, and London.

Kiadis Pharma

Venture Round in 2007
Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.

Intarcia Therapeutics

Series B in 2007
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

Genteric

Series A in 1997
Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.

Reef Point Systems

Venture Round in 2000
As of December 2007, Reef Point Systems, Inc. was acquired by NextPoint Networks, Inc. Reef Point Systems, Inc. provides security solutions for converged wireless and wireline networks in the United States. Its iQ product portfolio enables fixed/mobile convergence security, secure mobile access, network infrastructure protection, and managed security services. It enables operators to secure voice over the Internet protocol, Internet protocol television, and voice, video, and data services from a converged Internet protocol infrastructure. The company’s iQ family lets wireless service providers protect the wireless network infrastructure and deliver multimedia services for mobile users over unlicensed mobile access and Internet protocol multimedia subsystem infrastructure. Its products also enable service providers to offer various security services, including virtual private networks, firewalls, denial of service attack prevention, content filtering, and remote access. The company, formerly known as Quarry Technologies, Inc., was founded in 1998 and is headquartered in Burlington, Massachusetts.

aTyr Pharma

Series E in 2015
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

TransMedics

Series A in 2000
TransMedics, Inc. operates as a medical technology company. It offers organ care system, a multi-organ preservation technology that mirrors human physiology, minimizes ischemia, and provides the ability to optimize the organ during transport. The company is headquartered in Andover, Massachusetts.

DEM BioPharma

Series A in 2022
DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.

7TM Pharma

Series A in 2001
7TM Pharma is a biotech company that discovers and develops drugs with a primary therapeutic focus on diabetes, gastrointestinal, metabolic, asthma, and vascular diseases. The company offers seven transmembrane-spanning receptors, including TM38837, a small molecule CB1 receptor antagonist; TM30339, a NPY Y4 selective agonist that is used within gastrointestinal disorders, and short bowel syndrome; and CRTH2 antagonist, an oral drug for inflammatory or respiratory diseases. 7TM Pharma was founded in 2000 and is based in Lyngby, Hovedstaden.

Aegis Semiconductor

Series D in 2006
Aegis is a privately held company that builds solutions for embedded monitoring of advanced optical networks. The company's Active Thin Films are manufactured using proven high-volume processes with demonstrated high yield and superb uniformity. Aegis's solutions benefit from the reliability of solid-state, silicon-based design, extreme scalability, and low-cost packaging architectures.

Anesiva

Series C in 2002
Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management worldwide. Its lead product candidate includes Adlea, which completed multiple Phase II and Phase III trials for post-surgical, musculoskeletal, and neuropathic pain. The company was formerly known as AlgoRx Pharmaceuticals, Inc., it changed its name to Anesiva, Inc. in 2006. Anesiva, Inc. was founded in 1999 and is headquartered in South San Francisco, California. On January 15, 2010, Anesiva, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California. On June 10, 2014 filed for Chapter 7 bankruptcy.

Synad Technologies

Series B in 2002
Synad is a fast-growing UK startup that has rapidly revealed itself as one of the most successful WLAN fabless companies and one of the few able to deliver a full dual-band multi-standard solution. Synad has a proven multimode full CMOS production-ready chipset and reference design, and powerful software suites for both wireless-LAN access point and client applications.

nCircle Network Security

Series B in 2001
nCircle Network Security, Inc. provides agentless security risk and compliance management solutions. The company's products include IP360, the vulnerability and risk management solution that provides reporting, vulnerability prioritization, and remediation workflow designed to enable risk reduction; and Topology Risk Analyzer, which prioritizes vulnerabilities utilizing intelligence about the network layout. Its products also include Security Intelligence Hub, an open-architected reporting and integration point for collecting and sharing network intelligence across the enterprise security ecosystem; and nTellect, a threat prioritization system that leverages IP360's updated network intelligence to improve the accuracy and effectiveness of Cisco and McAfee's IDS and IPS. In addition, the company's products include Certified PCI Scan Service, an automated network security scan and reporting service, which enables customers to monitor and report on compliance with the PCI security standard; and Security Policy and Regulatory Compliance Solutions that compliance with internal security policies and automate security process, as well as support government- regulatory compliance solutions for FISMA and IAVA. It also provides configuration and regulatory compliance, reporting and analytics, and government solutions. The company offers vulnerabilities and exposures research team, consulting, and training services. Its security solutions are used by financial services, energy, utilities, retail, consumer goods, healthcare, pharmaceuticals, government, media, leisure, and technology enterprises, as well as government agencies and service providers to identify, measure, manage, and reduce security risk and automate compliance on their networks. The company was formerly known as Hiverworld, Inc. nCircle Network Security, Inc. was founded in 1998 and is headquartered in San Francisco, California with regional offices in Atlanta, Toronto, and London.

DispatchHealth

Private Placement in 2019
DispatchHealth Management, LLC provides on-demand mobile and virtual healthcare services. It offers services in the areas of acute injury and illness evaluation, laceration suture repair, injured extremity splinting, epistaxis treatment (nosebleeds), Foley catheter placement, G-tube placement, medication administration, laboratory testing, outpatient imaging arrangement (X-ray and CT scan), and primary care physician and home health agency coordination aspects. It serves patients and families. The company was formerly known as True North Health Navigation, LLC. DispatchHealth Management, LLC was founded in 2013 and is based in Denver, Colorado.

iSOCO

Venture Round in 2006
iSOCO is an international company that offers business solutions based on the design of cutting-edge technologies and strategic consultation to optimise relations between organisations and customers, suppliers, employees and partners and transform them into economic values. They build collaborative networks that integrate advanced technology which can create communities, facilitate communication, generate knowledge and connect opportunities. iSOCO has been recognised as a Key Vendor 2013 by Gartner for its virtual assistant. Furthermore in one of the spanish companies acredited as a official purchasing auditor into the framework of the new European Standard Purchasing.

Tacit Software

Venture Round in 2004
Tacit Software is a provider of collaboration and knowledge management software and the company behind illumio (www.illumio.com), a productivity tool for monitoring news, blogs, and wikis and connecting with others to share knowledge and expertise. illumio is used by individuals and organizations to more effectively discover and share information by delivering to users only what's important to them. Tacit's enterprise customers include some of the world's leading Fortune 500 companies including Lockheed Martin, Morgan Stanley, and Northrop Grumman.

Myocor

Series D in 2004
myocor is a medical company that develops and distributes a range of therapeutic products to its clients. The company develops and provides evaluations on technologies to treat mitral regurgitation and heart failure. Furthermore, the technologies assist in the improvement of cardiac function. myocor was founded in 1996 and is based in Minnesota.

ZS Pharma

Series D in 2014
ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood. ZS-9 is currently being tested in late-stage clinical trials.

Lumena Pharmaceuticals

Series B in 2014
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults.

Be Biopharma

Private Placement in 2020
Be Biopharma, Inc. develops therapeutics for diseases from engineered B-cells in the immune system. It can overcome the drawbacks of current cell and gene therapies, including the inability to provide multiple doses, unpredictable chemical reactions in some individuals, and the need for chemotherapy regimens prior to cell therapies that can be dangerous to patients. The company applies its technology to diseases, including cancer, autoimmune disorders, and infectious diseases. The company was incorporated in 2020 and is based in Cambridge, Massachusetts.

Sonexa Therapeutics

Series A in 2008
Sonexa Therapeutics, Inc., a pharmaceutical company, engages in the development of therapeutics drugs for the treatment of Alzheimer's disease and related disorders. It develops ST101, a small and orally active molecule compound that penetrates the blood-brain-barrier. The company was incorporated in 2007 and is based in San Diego, California.

Lassen Therapeutics

Series A in 2020
Lassen Therapeutics develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. The company’s lead candidate is LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor alpha (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be more effective than targeting other factors such as TGF-β and CTGF. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells.

Arrow Therapeutics

Series B in 2003
Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

Nereus Pharmaceuticals

Series D in 2005
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

Phenomix

Series A in 2003
As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

VertiFlex

Series C in 2008
VertiFlex, Inc., a medical device company, provides minimally invasive and motion preserving spinal surgery technologies in the United States and internationally. The company offers superion interspinous spacer, a percutaneous titanium implant that fits between the spinous processes in the lumbar spine. Its Superion is a motion-preserving interspinous spacer for the treatment of moderate spinal stenosis. Vertiflex Inc was founded in 2005 and is headquartered in California, USA.

USGI Medical

Series C in 2006
USGI Medical, Inc. engages in the development of technologies that enable surgeons and gastroenterologists to perform procedures through the body's natural passageways. The company offers specialized tools to perform minimally invasive procedures through a patient's mouth or other natural orifices. It offers its products obesity, natural orifice translumenal endoscopic surgery, and gastroesophageal reflux disease. The company was incorporated in 2001 and is based in San Clemente, California.

Allakos

Series A in 2014
Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.

Cara Therapeutics

Series D in 2010
Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

Aevi Genomic Medicine

Series A in 2001
Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies. It is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics at The Children's Hospital of Philadelphia.

Kiadis Pharma

Venture Round in 2012
Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.

ChemGenex Pharmaceuticals

Series A in 2007
ChemGenex Pharmaceuticals Ltd, an integrated biopharmaceutical development company, engages in the discovery and the development of oncology drugs. The company's product candidates include omacetaxine mepesuccinate, an investigational small molecule agent that is in Phase 2/3 clinical trial for the treatment of chronic myelogenous leukemia, and is also in Phase 2 clinical trials for the treatment of acute myelogenous leukemia and myelodysplastic syndrome; and Quinamed, which is in Phase 2 clinical trial for the treatment of hormone refractory prostate cancer. It was formerly known as AGT Biosciences Limited and changed its name to ChemGenex Pharmaceuticals Ltd in June 2004. The company was founded in 1958 and is headquartered in Geelong, Australia.

NeurogesX

Series D in 2005
NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel non-opioid, pain management therapies to address unmet medical needs. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is based in San Mateo, California.

MacroGenics

Series D in 2008
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Vir Biotechnology

Venture Round in 2017
Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.

OPAL Therapeutics

Series A in 2005
OPAL Therapeutics Pty Limited operates as an immunotherapy development company in Australia. It develops therapies for the treatment of human immunodeficiency virus, Hepatitis C, and chronic infection. OPAL Therapeutics Pty Limited was incorporated in 2005 and is based in Melbourne, Australia.

Agensys

Series C in 2002
Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.

Esperion

Venture Round in 2013
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

aTyr Pharma

Series C in 2010
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Intarcia Therapeutics

Series E in 2004
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

Coapt Systems

Series B in 2002
Coapt Systems, Inc. engages in the design, development, manufacture, and marketing of bio-absorbable implants for use in soft tissue fixation during facial cosmetic surgery procedures. It offers ENDOTINE Forehead 3.0, a bioabsorbable brow fixation device; ENDOTINE Forehead Instrument Kits that comprise insertion tools, drill bits, and sterilization trays with lids; ENDOTINE Triple 3.0, the bioabsorbable brow fixation devices with disposable drill bits and insertion tools; ENDOTINE TransBleph 3.0, a bioabsorbable upper lid and brow fixation devices. The company also provides ENDOTINE Midface ST 4.5, a bioabsorbable midface suspension devices; ENDOTINE Ribbon, a bioabsorbable fixation devices; Coapt Manual Surgical Drills, the manual surgical hand drills for use with ENDOTINE implants; and SurgiWire Incisionless Dissectors, the subcutaneous The Endotine product line was bought by MicroAire, a surgical device manufacturer in Charlottesville, VA, in August 2010.

Alba Therapeutics

Series A in 2005
Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba’s technology is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, asthma/COPD and acute lung injury.

Tacit Knowledge

Series A in 2004
Tacit Knowledge is the digital commerce consultancy that delivers Silicon Valley innovation to retail organizations around the world. Founded in 1997 by a group of software engineers, Tacit implements packaged applications and builds custom software for globally recognized multichannel organizations, including some of Internet Retailer's Top 25. The company is headquartered in San Francisco with offices in New York, London, Guadalajara, and Chisinau.

Insulet

Series E in 2006
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.